Clinical trial
Toripalimab Plus Axitinib Induction Therapy With Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma: A Prospective, Single-Arm, Phase II Study (TACTIC-RCC)
NCT07776717 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Toripalimab Plus Axitinib Induction Therapy With Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell Carcinoma: A Prospective, Single-Arm, Phase II Study (TACTIC-RCC)
- Lead sponsor
- Fudan University
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- August 20, 2026
- Completion date
- December 31, 2028
- Enrollment
- 30 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
advanced clear cell renal cell carcinoma, metastatic clear cell renal cell carcinoma